MIM
VTGN icon

MetLife Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

MetLife Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,443
Closed -$117K – 2844
2022
Q2 		$117K Hold
4,443
– – ﹤0.01% 2647
2022
Q1 		$165K Buy
4,443
+1,640
+59% +$71.5K ﹤0.01% 2466
2021
Q4 		$164K Hold
2,803
– – ﹤0.01% 2175
2021
Q3 		$230K Hold
2,803
– – ﹤0.01% 2003
2021
Q2 		$265K Buy
+2,803
New +$208K ﹤0.01% 1975

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's VTGN Position: Q3 2022 in Review

MetLife Investment Management sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 4,443 shares — an estimated $117K sold.

MetLife Investment Management first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $265K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • MetLife Investment Management reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • MetLife Investment Management sold 4,443 VistaGen Therapeutics shares in Q3 2022, an estimated $117K.
  • MetLife Investment Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • MetLife Investment Management's VistaGen Therapeutics position peaked at $265K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on MetLife Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.